Posted on by Mike Yeomans
BlueSphere licensed technology from the lab of Mark Shlomchik, chair of the Department of Immunology at the Pitt Medical School, aimed at developing personalized T-cell therapies for cancer and other …
Posted on by Mike Yeomans
Forge Biologics, a Columbus, Ohio-based gene therapy manufacturing and development company, is set to begin Phase I and 2 clinical trials of a gene therapy to treat Krabbe Disease, a …
Posted on by Mike Yeomans
LifeX Labs has leased 5,000 square feet in the Chocolate Factory complex in Lawrenceville to begin offering wet lab space that will be able to accommodate up to 20 startups.
Posted on by Mike Yeomans
Posted on by Mike Yeomans
Posted on by Mike Yeomans
Posted on by Mike Yeomans
Posted on by Mike Yeomans
Posted on by Karen Woolstrum
Media Release HiberSense Wins $10K in AUTM Venture Challenge AUSTIN, Texas – February 14, 2019 — HiberSense, Inc., a start-up from the University of Pittsburgh Innovation Institute, has won the $10,000 top prize in AUTM’s Pitch and Play business plan competition at the Association’s 2019 Annual Meeting in Austin, Texas. New company creation and development […]
Posted on by Mike Yeomans
Posted on by Mike Yeomans
February 11, 2019 The University of Pittsburgh announced that Pitt innovators were issued 17 U.S. patents in January 2019. Featured Patent: U.S. 10,167,519 “Fusion Gene Associated with Progressive Prostate Cancer” Jianhua Luo, professor in the Department of Pathology, and colleagues have developed methods and compositions for determining whether a person having prostate cancer is at […]
Posted on by Mike Yeomans